Clinical trials
High-Risk Localized Prostate Cancer clinical trials
Below are recruiting high-risk localized prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 107 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06682728RecruitingPhase 2
Treating high-risk bladder cancer after surgery
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
Orange, CaliforniaAges 18 years+ - NCT06696794RecruitingPhase 3
Testing mitomycin before surgery for high-risk bladder cancer
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
Wuhan, HubeiAges 18–75 - NCT05394337RecruitingPhase 1/Phase 2
Immunotherapy before bladder surgery for cisplatin-ineligible patients
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
Houston, TexasAges 18 years+ - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Baltimore, MarylandAges 12 years+ - NCT04617756RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk upper urinary tract cancer
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Paris, Paris Cx 20Ages 18 years+ - NCT05840484Recruiting
Monitoring study for men on active surveillance
This trial follows men with prostate cancer who choose “active surveillance” instead of immediate treatment. It tests whether careful tracking (including patient reports) can help manage cancer over time and guide decision-making.
Houston, TexasAges 18 years+ - NCT07049848RecruitingPhase 2
Study of atezolizumab with chemo and radiation for high-risk sarcoma
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
Houston, TexasAges 18 years+ - NCT07445048RecruitingPhase 3
Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
ShanghaiAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Birmingham, AlabamaAges 18 years+ - NCT05912816RecruitingPhase 2
Kidney-protecting treatment for high-risk upper urinary tract cancer
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT05800366RecruitingPhase 2
Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Miami, FloridaAges 18 years+ - NCT06092957RecruitingPhase 3
Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06319196RecruitingPhase 2
Clearing melanoma with immunotherapy after surgery
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
Toronto, OntarioAges 18 years+ - NCT06483906RecruitingPhase 2
Study of a drug combo and stem cell transplant for high-risk AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06509945Recruiting
Donor stem cell transplant for high-risk T-cell lymphoma
This trial tests giving a donor stem cell transplant (called allo-PBSCT) as the first treatment after chemotherapy for people with high-risk peripheral T-cell lymphoma. It may help prevent the lymphoma from coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06835049RecruitingPhase 2
Heating therapy before surgery for high-risk soft tissue sarcoma
This trial tests a new approach for high-risk soft tissue sarcoma of the arm, leg, or trunk. Before surgery, you would receive chemotherapy combined with local hyperthermia (a treatment that gently heats the tumor area) to see if this can improve outcomes.
AarauAges 18 years+ - NCT06932757RecruitingPhase 2
Quisinostat after treatment for high-risk uveal melanoma
This trial tests whether taking quisinostat pills after standard treatment can lower the chance of uveal melanoma coming back in people whose original tumor had high-risk features. It is for patients who have finished their eye treatment (surgery or radiation) within the past 6 months and have no signs that the cancer has spread.
Miami, FloridaAges 19 years+ - NCT06977711RecruitingPhase 1
Testing a new drug combo for high-risk DLBCL
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
San Antonio, TexasAges 18 years+ - NCT07077239Recruiting
Adaptive radiation after prostate surgery to lower side effects
This trial tests a precise, short-course radiation treatment (stereotactic body radiotherapy) after prostate removal surgery that adapts to your body each day to reduce side effects. It is for people whose prostate cancer has high-risk features or a rising PSA after surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT07163910RecruitingPhase 2
Homoharringtonine plus hormone therapy before prostate surgery
This trial tests whether adding a drug called homoharringtonine (a type of chemotherapy) to standard hormone therapy before prostate surgery can improve outcomes for men with certain stages of prostate cancer. It's for men who haven't had any previous treatment and plan to have their prostate removed.
Nanjing, JiangsuAges 18–85 - NCT07617272RecruitingPhase 2
Testing a drug to shrink high-risk prostate cancer before surgery
This trial tests whether a hormone-blocking drug called darolutamide can shrink aggressive prostate cancer before surgery. Researchers will also use a special blood test to predict who benefits most from the treatment.
GothenburgAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT07364071RecruitingPhase 2
Hormone therapy and targeted radiation for high-risk prostate cancer
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
La Jolla, CaliforniaAges 18 years+ - NCT00913939Recruiting
MRI-guided high-dose-rate treatment for recurrent prostate cancer
This study tests a targeted radiation approach called high-dose-rate (HDR) brachytherapy, guided by MRI, for certain people with recurrent or higher-risk prostate cancer. It may help deliver radiation more precisely, depending on your cancer type and prior treatments.
Toronto, OntarioAges 18 years+
Hear when a new High-Risk Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high-risk localized prostate cancer?
- Yes. Clin2 currently lists 107 recruiting high-risk localized prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high-risk localized prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high-risk localized prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.